Medical Affairs consultancy LUCENT Biopharma has appointed Simon Doyle as chief executive officer with immediate effect, with founder and outgoing chief executive Dr Matthew Goodman transitioning to the role of Chief Medical Officer and remaining a core member of the leadership team, according to PR Newswire.

Founded in 2022, LUCENT provides specialist Medical Affairs support to biotechnology and pharmaceutical companies across the US, UK, and Europe. The leadership change is designed to support the delivery of the company's three-year growth strategy while preserving its scientific credibility and client-focused culture.

Simon Doyle, who brings experience from STEM, NeoHealthHub, and Cencora, said: "Having worked closely with LUCENT, I've seen first-hand the strength of its model and the calibre of its people. As CEO my focus will be on scaling the business in a way that preserves its entrepreneurial spirit and commitment to excellence."

Goodman said: "From the outset, my ambition for LUCENT was to build a consultancy defined by its scientific credibility and ability to truly deliver for clients. Bringing Simon into this leadership position feels like a natural evolution his strategic insight and experience will be instrumental in scaling the business, while I focus on ensuring we continue to deliver the highest standard of Medical Affairs expertise to our clients."

The appointment marks a significant step in LUCENT's ambition to build a world-class Medical Affairs consultancy. Central to the company's model is a medical-led team structure, ensuring all functions remain aligned to client needs and real-world clinical challenges across the pharmaceutical and biotechnology sectors.

Read the full report for further detail on the LUCENT Biopharma leadership transition and growth strategy.